BriaCell Therapeutics (BCT) investor relations material

Executive summary

• Advanced pivotal Phase 3 trial of Bria-IMT immunotherapy in metastatic breast cancer, with enrollment surpassing 230 patients and multiple positive safety reviews; Fast Track Designation maintained by FDA.

• Reported extended survival in heavily pretreated metastatic breast cancer patients, with several exceeding 18-47 months post-enrollment, and no treatment-related discontinuations.

• Expanded Bria-OTS and Bria-OTS+ platform, including FDA clearance to initiate clinical evaluation of Bria-BRES+ in metastatic breast cancer and completion of manufacturing for Bria-PROS+ for prostate cancer.

• Entered a definitive agreement for BriaPro to acquire exclusive rights to develop and commercialize Soluble CD80, increasing BriaCell's stake in BriaPro to 78%.

Financial highlights

• For the quarter ended April 30, 2026: Net loss of $7.2M, up from $6.2M in Q3 2025; net loss per share of $(0.99) vs. $(16.42) prior year.

• Nine months ended April 30, 2026: Net loss of $22.8M, up from $18.4M year-over-year; net loss per share of $(5.73) vs. $(67.08) prior year.

• Operating expenses for the quarter rose to $7.6M from $6.3M, driven by higher R&D and clinical trial costs.

• Cash and cash equivalents at $6.9M as of April 30, 2026, down from $10.5M at July 31, 2025; working capital of $21.8M.

• Raised $30M in January 2026 public offering and $4.7M in June 2026, supporting ongoing operations.

Outlook and guidance

• Continued focus on advancing pivotal Phase 3 Bria-IMT trial and expanding Bria-OTS/OTS+ platforms.

• Plans to initiate Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancer following FDA clearance.

• Ongoing efforts to secure additional capital to fund operations amid continued operating losses.